ATLANTA, Feb. 23 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today that it will host a conference call on Thursday, March 2, 2006 at 8:30 a.m. Eastern Time to review the Company's fourth quarter and year ended December 31, 2005 financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its fourth quarter and year-end financial results on the same day, prior to the conference call.
To access the conference call, please dial 800-299-7089 (domestic) or 617-801-9714 (international) and reference the access code 31952272. A replay of the call will be available from 10:30 a.m. Eastern Time on March 2, until April 2, 2006 at midnight. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 11286020. A live audio webcast of the call and the archived webcast will be available in the Investors section of the Inhibitex website http://www.inhibitex.com under the Upcoming Events category.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. The Company currently has six drug development programs, all of which are based on its proprietary MSCRAMM protein platform technology. The Company's clinical-stage product candidates are Veronate, which is currently the subject of a pivotal Phase III clinical trial for the prevention of hospital-associated infections in very low birth weight infants, and Aurexis, which is being evaluated in clinical trials for the treatment of serious Staphylococcus aureus (S. aureus) bloodstream infections. The Company has retained all world-wide rights to Veronate and Aurexis, both of which have been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Veronate has also been designated an Orphan Drug by the FDA and an Orphan Medicinal Product (OMP) by the European Medicines Agency. The Company's preclinical programs include a collaboration and joint development agreement with Dyax Corp. to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
Contacts: Inhibitex, Inc. Russell H. Plumb Chief Financial Officer (678) 746-1136 rplumb@inhibitex.com Lilian Stern (Investors) Stern Investor Relations, Inc. (212) 362-1200, lilian@sternir.com Kathryn Morris (Media) KMorrisPR (845) 635-9828 kathryn@kmorrispr.com
Inhibitex, Inc.CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Lilian Stern ofStern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com; orMedia, Kathryn Morris of KMorrisPR, +1-845-635-9828, orkathryn@kmorrispr.com
Web site: http://www.inhibitex.com/
